TCRX

Tscan Therapeutics Inc
NASDAQHEALTHCAREBIOTECHNOLOGY

Key Statistics

Market Cap
$69.92M
P/E Ratio
EPS
$-0.96
Beta
1.04
52W High
$2.57
52W Low
$0.82
50-Day MA
$1.05
200-Day MA
$1.22
Dividend Yield
Profit Margin
0.00%
Forward P/E
PEG Ratio

About Tscan Therapeutics Inc

Tscan Therapeutics Inc (TCRX) is a clinical-stage biotechnology company at the forefront of precision cancer treatment, utilizing its innovative T cell receptor (TCR) discovery platform to specifically target cancer antigens. Committed to advancing TCR-based therapeutics, Tscan is actively developing a diverse pipeline aimed at addressing various malignancies and improving patient outcomes. The company's robust intellectual property portfolio and strategic focus position it favorably within the rapidly evolving T cell-based immunotherapy landscape, addressing critical unmet medical needs in oncology.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$9.14M
Gross Profit (TTM)$-95.53M
EBITDA$-123.82M
Operating Margin-2967.00%
Return on Equity-80.90%
Return on Assets-29.60%
Revenue/Share (TTM)$0.15
Book Value$1.61
Price-to-Book0.71
Price-to-Sales (TTM)7.65
EV/Revenue3.694
EV/EBITDA0.39
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)-54.80%
Shares Outstanding$61.07M
Float$55.39M
% Insiders0.20%
% Institutions59.46%

Historical Volatility

HV 10-Day
118.10%
HV 20-Day
107.25%
HV 30-Day
92.33%
HV 60-Day
93.08%
HV Rank

Volatility is currently expanding

Analyst Ratings

Consensus ($6.00 target)
1
Strong Buy
4
Buy
1
Hold

Latest News

TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

WALTHAM, Mass., June 24, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on Tuesday, June 30, 2026 at 11:30 a.m. Eastern Time.

GlobeNewsWire6/24/2026Neutral
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies

SOUTH SAN FRANCISCO, Calif. & WALTHAM, Mass.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced an agreement to evaluate automated clinical manufacturing of TSC-101, TScan's lead TCR-T therapy candidate for patients wit.

Business Wire6/3/2026Neutral
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting

WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of an abstract for poster presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 29ᵗʰ Annual Meeting being held May 11 – 15 in Boston, MA as well as virtually.

GlobeNewsWire4/27/2026Neutral
TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

WALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026 at 3:00 p.m. Eastern Time.

GlobeNewsWire4/8/2026Neutral

More HEALTHCARE Stocks

Data last updated: 7/9/2026